What is more likely to cause akathisia, Thorazine (chlorpromazine) or Invega Sustenna (paliperidone)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Akathisia Risk: Thorazine vs. Invega Sustenna

Thorazine (chlorpromazine) is more likely to cause akathisia than Invega Sustenna (paliperidone) due to its classification as a low-potency conventional antipsychotic with higher rates of extrapyramidal side effects. 1

Mechanism and Risk Factors for Akathisia

Akathisia is characterized by:

  • A sense of severe restlessness
  • Physical agitation (often manifesting as pacing)
  • Subjective distress
  • Difficulty remaining still

Comparison of Medications

Thorazine (Chlorpromazine):

  • First-generation/conventional antipsychotic
  • Low-potency agent with significant dopamine D2 receptor blockade
  • Higher risk of extrapyramidal symptoms including akathisia
  • Often misinterpreted as psychotic agitation or anxiety
  • Common reason for medication noncompliance 1

Invega Sustenna (Paliperidone):

  • Second-generation/atypical antipsychotic (long-acting injectable)
  • More balanced receptor profile with less D2 blockade
  • Lower incidence of extrapyramidal symptoms
  • Better tolerated regarding movement disorders
  • Still carries some risk of akathisia, but significantly less than conventional antipsychotics 2

Evidence-Based Comparison

The American Academy of Child and Adolescent Psychiatry guidelines note that conventional antipsychotics like chlorpromazine have a higher incidence of extrapyramidal side effects, including akathisia 1. While second-generation antipsychotics (SGAs) like paliperidone were developed specifically to reduce these side effects.

Research indicates that SGAs produce akathisia at composite rates ranging from 2.9-13.0% across studies, compared to higher rates with conventional agents like chlorpromazine 3. The risk of akathisia with SGAs is approximately half that of conventional antipsychotics, though it still occurs.

Clinical Implications

Management Considerations:

  • If akathisia develops:
    • Consider dose reduction if clinically feasible
    • Antiparkinsonian agents may help but are not consistently effective
    • β-blockers (particularly propranolol) and benzodiazepines have shown benefit
    • Low-dose mirtazapine may be effective for treatment 4

Monitoring:

  • Assess for restlessness, inability to sit still, pacing
  • Ask about subjective feelings of inner restlessness or tension
  • Monitor particularly after initiation or dose increases
  • Be aware that akathisia is often misdiagnosed as anxiety or agitation 1

Important Caveats

  • High doses of any antipsychotic increase akathisia risk 3
  • Individual patient factors may influence susceptibility
  • Akathisia can occur with all antipsychotics, but at different rates
  • Young age and male gender are risk factors for extrapyramidal symptoms 1
  • Akathisia is a common reason for medication noncompliance and should be addressed promptly

In summary, while both medications can cause akathisia, Thorazine (chlorpromazine) poses a substantially higher risk compared to Invega Sustenna (paliperidone), making the latter a better choice when akathisia is a specific concern.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension.

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.